Business Wire

Affise Launches New Attribution Chain Technology to Measure Advertising Results

10.5.2021 12:00:00 EEST | Business Wire | Press release

Share

Affise launched a new type of attribution chain technology to measure mobile advertising attribution without the previously required user device identifier for advertisers (IDFA). The removal of the IDFA results from Apple’s App Tracking Transparency (ATT) roll-out.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005320/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Affise New Attribution Chain Technology (Photo: Business Wire)

Initially expected in summer 2020 and later moved to 2021, the iOS14.5 release introduced the ATT policy, which from the moment of roll-out requires every app to get explicit permission from users to access their IDFA. In practical terms, requiring user opt-in eliminates the large part of data vital for end-user identification. Attribution platforms can no longer store and pass user information to an advertiser and back.

These terms leave advertisers with an insufficient amount of data to measure campaign performance and evaluate the efficiency of mobile ads. This could likely affect the efficiency of targeted ads and further decrease the revenue of app publishers.

To alleviate the impact and allow attribution and ad measurement, Apple introduced SKAdNetwork, a privacy-friendly method to measure mobile campaigns’ attribution on iOS apps. The other alternative supported by most MMPs is probabilistic attribution, which relies on the statistics and probability distribution of all the campaigns likely to have generated an install.

Affise announces privacy-enabled attribution chain to support redirects data transfer

Dmitrii Zotov, CTO of Affise, said: “The future of mobile attribution on iOS became the most debated issue and we got actively involved in implementing timely solutions that would allow advertisers and ad networks to attribute app installs. So far, we support both probabilistic attribution from all the MMPs and SKAdNetwork integration. Further, we want to ensure that conversion data will not be lost in a chain of attribution between publishers. Thus we release the privacy-enabled attribution chain, which helps determine conversion along the chain of publishers.”

Apple’s ATT policy may have severe implications on the whole industry, but user privacy is everything nowadays and we should expect major changes around this trend. Meanwhile, advertisers still need to measure conversions, work with traffic suppliers and correctly assign payouts, especially when working with multiple publishers in the chain. By losing the ability to correlate click and conversion, we also lose the ability to relay any past performance data to the publisher.

With MMPs’ restrictions to transfer data only at the source and sub-source level, Affise developed a solution that will support all redirect data transfer. The Affise attribution chain solution uses a particular format of integration macros to pass all the publisher’s data in a simple format.

The attribution chain method protects users’ privacy while ensuring a fair and accurate attribution process for advertising market players.

The macros include all the information needed by the network to determine campaign and traffic source. This means that multiple publishers in the attribution chain will have access to conversion data and will be able to successfully optimize their traffic, where advertisers can ensure the effectiveness of their performance campaigns.

About Affise

Affise is a partnership marketing platform for brands, advertisers and agencies to automate and scale their partner relations via all possible performance marketing channels: traditional affiliates, influencers, networks and agencies. The synergy of technology and the long standing experience allows Affise’s clients to make partnerships manageable and revenue predictable marketing channel. To learn more, visit www.affise.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Yulia Dobyshuk
y.dobyshuk@affise.com
+45 42 44 67 83

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye